Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Trastuzumab
Related studies linked through entity extraction aliases.
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
ctDNA in HER2+ EBC Neoadjuvant Treatment
- Status
- RECRUITING
- Phase
- PHASE2
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
- Status
- RECRUITING
- Phase
- PHASE3
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2